Marshall Wace, LLP Spring Works Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,333,117 shares of SWTX stock, worth $75.3 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,333,117
Previous 2,966,622
21.35%
Holding current value
$75.3 Million
Previous $146 Million
39.81%
% of portfolio
0.12%
Previous 0.23%
Shares
12 transactions
Others Institutions Holding SWTX
# of Institutions
221Shares Held
66.8MCall Options Held
64.7KPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA6.54MShares$211 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$181 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.7MShares$119 Million4.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.6MShares$116 Million0.02% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$110 Million7.16% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.01B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...